Please assess the completion status of the following clinical trial:

Trial Title: OK 2004 Study (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV patients \> 18 years old who provide signed and dated Informed consent.~* HIV patients who have been receiving lopinavir/ritonavir and two nucleosides during at least 4 weeks.~* Plasma HIV RNA \< 50 cop/ml for six months~Exclusion Criteria:~* HIV patients who have stopped a protease inhibitor due to virological failure.~* HIV patients with hepatic or renal insufficiency.~* HIV patients with positive serum HBVAg~* HIV patients who require treatment with a lopinavir/r contraindicated medication.~* HIV pregnant or breastfeeding women.~* Active drug abuse (including alcohol or recreational drugs). Exception, cannabis, provided the investigator is confident in patient adherence. Patients under Methadone program will be accepted too if deemed appropriate by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).